PCRX: Pacira BioSciences, Inc. Stock

by  •  • Comments Off on PCRX: Pacira BioSciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,155.52
Enterprise Value ($M) 1,464.06
Book Value ($M) 778.35
Book Value / Share 16.82
Price / Book 1.48
NCAV ($M) -30.04
NCAV / Share -0.65
Price / NCAV -38.47

Profitability (mra)
Return on Invested Capital (ROIC) -0.07
Return on Assets (ROA) -0.06
Return on Equity (ROE) -0.11

Liquidity (mrq)
Quick Ratio 2.00
Current Ratio 2.40

Balance Sheet (mrq) ($M)
Current Assets 745.13
Assets 1,553.52
Liabilities 775.17
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 700.97
Operating Income 97.57
Net Income -99.56
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 189.39
Cash from Investing -83.28
Cash from Financing 17.36

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-15 13G Millennium Management Llc 5.10

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2024 Or ☐ TRANSITION REPORT PU
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPO
2024-07-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-15 70,748 347,696 20.35
2025-04-14 172,489 813,086 21.21
2025-04-11 74,661 511,296 14.60
2025-04-10 296,739 1,310,155 22.65

(click for more detail)

Similar Companies
ORIC – ORIC Pharmaceuticals, Inc. OVID – Ovid Therapeutics Inc.
PBYI – Puma Biotechnology, Inc. PCVX – Vaxcyte, Inc.
PEPG – PepGen Inc.


Financial data and stock pages provided by
Fintel.io